
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences is a promising clinical-stage biotechnology company with a diversified pipeline and an innovative gene circuit platform. The strong efficacy data observed in its Phase 1 trial for their lead candidate SENTI-202, paired with their successful FDA RMAT meeting and finalized pivotal strategy, position them well for potential future success in the treatment of blood cancers. However, financing remains a key near-term risk for the company and potential safety issues and resistance could lead to downward revisions of their PT.
Bears say
Senti Biosciences is a clinical stage biotechnology company that has been developing cell and gene therapies using its gene circuit platform for patients with incurable diseases since 2016. Their current product pipeline includes SENTI-202, a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, and SENTI-301A for GPC3+ hepatocellular carcinoma, with a focus on donor-derived natural killer (NK) cells for oncology indications. However, there are risks to their success, including unanticipated toxicities in clinical trials, potential competition from other companies in the cell therapy space, and the need for ongoing financing which may lead to share dilution for shareholders.
This aggregate rating is based on analysts' research of Senti Biosciences Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares